The tissue-type plasminogen activator story.
Milestones in the development of tissue-type plasminogen activator (t-PA) as a fibrin-specific thrombolytic agent include: purification of human t-PA from the culture fluid of the Bowes melanoma cell line, elucidation of the molecular basis of fibrin-specific plasminogen activation, first experimental animal models of thrombosis, first patient (renal allograft) treated with melanoma t-PA, pilot studies in patients with acute myocardial infarction, cloning and expression of recombinant t-PA providing sufficient amounts for large scale clinical use, and demonstration of its therapeutic benefit in large multicenter clinical trials.
Collen
D
D
Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg, O & N 1, Herestraat 49 Box 911, B-3000 Leuven, Belgium. desire.collen@med.kuleuven.be
Lijnen
H R
HR
D000818:Animals; D005343:Fibrinolytic Agents / Q000266:history* / Q000627:therapeutic use; D049673:History, 20th Century; D006801:Humans; D011994:Recombinant Proteins / Q000138:chemical synthesis / Q000266:history / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000266:history* / Q000379:methods; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy / Q000266:history*; D010959:Tissue Plasminogen Activator / Q000138:chemical synthesis / Q000266:history* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator